6 results match your criteria: "Novartis Institute for Biomedical Research Vienna[Affiliation]"
Immunol Lett
January 2005
Novartis Institute for BioMedical Research Vienna, Brunner Strasse 59, A-1235 Vienna, Austria.
The 1-phosphates of sphingosine and ceramide (S1P and C1P) have emerged as key representatives of a new group of lipid signalling molecules. S1P is known to act both as an extracellular mediator and as an intracellular 'second messenger,' while C1P currently is only known for its intracellular actions. Therefore, sphingosine and ceramide kinases, the enzymes involved in the generation of these lipid mediators, are now in the spotlight.
View Article and Find Full Text PDFBiochem Biophys Res Commun
November 2004
Novartis Institute for BioMedical Research Vienna, Brunnerstrasse 59, A-1235 Vienna, Austria.
The N-terminus of ceramide kinase (CERK) is thought to be myristoylated and to contain a pleckstrin homology (PH) domain. We found that deletion of this region (DeltaPH-CERK) ablates activity. This is not due to prevention of N-terminal myristoylation since a G2A CERK mutant, which cannot be myristoylated, was active.
View Article and Find Full Text PDFCurr Opin Chem Biol
August 2004
Novartis Institute for Biomedical Research--Vienna Discovery Technologies, Innovative Screening Technologies Unit, A-1235, Vienna, Brunner Strasse 59, Austria.
Chemical biology has emerged as a new scientific discipline to change the way scientists approach and study the interface between chemistry, biology, and physics. By integrating the knowledge base of the human genome with the power of diverse and flexible chemical technology platforms, the ultimate goal is to define the 'rules of engagement' for small molecules and their use in basic biology and in drug discovery. Herein, we highlight the current counterpoles of the chemical biology philosophy in the framework between conformational diversity and informational complexity.
View Article and Find Full Text PDFJ Med Chem
August 2004
Novartis Institute for Biomedical Research Vienna, Brunnerstrasse 59, A-1235 Vienna, Austria.
Steroid sulfatase (STS) is an attractive target for the potential therapy of a number of estrogen- and androgen-dependent disorders. Most potent STS inhibitors known so far act as irreversible enzyme blockers and feature an aryl sulfamate moiety; even minor modifications at the sulfamate group result in drastically decreased activity. On the basis of a recently reported subclass of highly potent STS inhibitors, i.
View Article and Find Full Text PDFJ Allergy Clin Immunol
May 2004
Novartis Institute for Biomedical Research-Vienna, Brunnerstrasse 59, A-1235 Vienna, Austria.
Background: The transcription factor T-bet mediates IFN-gamma production by T(H)1 cells and suppresses T(H)2 cytokine production when ectopically expressed in polarized murine T(H)2 cells. Thus T-bet-mediated inhibition of T(H)2 cytokine production might be beneficial for the treatment of allergic diseases like asthma or atopic dermatitis.
Objective: We sought to investigate the effects of ectopic T-bet expression in highly polarized human T(H)2 cells obtained from skin biopsy specimens of patients with atopic dermatitis.
Assay Drug Dev Technol
February 2004
Dermatology & Immunopathology, Novartis Institute for Biomedical Research Vienna, Vienna, Austria.
Steroid sulfatase is an enzyme that currently enjoys considerable interest as a potential drug target in the treatment of estrogen- and androgen-dependent diseases, in particular breast cancer. We have purified human steroid sulfatase to apparent homogeneity from recombinant Chinese hamster ovary cells, and we established an assay with a new fluorogenic substrate, 3,4-benzocoumarin-7-O-sulfate (1). Substrate 1 features a K(m) value of 22.
View Article and Find Full Text PDF